Sanofi SA (SASY.PA)
84.51EUR
24 May 2013
€-0.30 (-0.35%)
€84.81
€85.00
€85.64
€84.09
2,341,080
2,846,541
€86.43
€53.20
SASY.PA
About
Overall
| Beta: | 0.53 |
| Market Cap (Mil.): | €112,412.60 |
| Shares Outstanding (Mil.): | 1,330.16 |
| Dividend: | 2.77 |
| Yield (%): | 3.28 |
Financials
| SASY.PA | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 26.92 | 34.04 | 34.30 |
| EPS (TTM): | 3.14 | -- | -- |
| ROI: | -- | 19.04 | 18.43 |
| ROE: | -- | 19.78 | 19.30 |
REFILE-Sanofi says will back overhaul of Toulouse research site
(Changes 'keep' to 'back overhaul of' in headline; changes wording of paragraph 7 to remove reference to retaining site)
Sanofi says will keep Toulouse research site
PARIS - Sanofi said it would overhaul rather than exit its Toulouse research site, as it seeks to break an impasse with the French government which opposed the drugmaker's reorganization plans and the loss of jobs.
Sanofi says myelofibrosis treatment study positive
PARIS, May 17 - French drugmaker Sanofi said a late-stage Phase III trial of a drug designed to treat myelofibrosis led to positive results.
Sanofi recruits patients for arthritis trials
PARIS - French drugmaker Sanofi SA said it and U.S. firm Regeneron Pharmaceuticals have started recruiting patients for two new trials of their arthritis treatment sarilumab.
FDA approves labels with lower doses for zolpidem sleep drugs
- The Food and Drug Administration approved label changes incorporating lower dosages for sleep medications containing zolpidem, a drug that can continue to affect patients' mental alertness even a day after its use.
UPDATE 1-Sanofi fined in Plavix generics dispute
* Sanofi may appeal decision, shares down 0.6 percent (Adds details, Sanofi comments, shares)
Sanofi may appeal French competition body fine
PARIS, May 14 - French drugmaker Sanofi said on Tuesday it objected to a fine by the French Competition Authority in a dispute over generic competition to its blood thinner, Plavix, and said it was considering a possible appeal.
French competition body fines Sanofi in Plavix dispute
PARIS - The French Competition Authority said on Tuesday it fined drugmaker Sanofi 40.6 million euros ($52.7 million) over what it called a smear campaign aimed at stifling generic competition to its blood thinner, Plavix.
French competition body fines Sanofi in Plavix dispute
PARIS, May 14 - The French Competition Authority said on Tuesday it fined drugmaker Sanofi 40.6 million euros ($52.7 million) over what it called a smear campaign aimed at stifling generic competition to its blood thinner, Plavix.
European shares slip from multi-year highs
* FTSEurofirst 300 down 0.1 pct, Euro STOXX 50 down 0.5 pct
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (SNY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
